Elecsys pTau181 is the first In Vitro Diagnostic Regulation (IVDR) certified test to rule out Alzheimer’s associated amyloid pathology.The minimally invasive, blood-based test can serve as a rule out for Alzheimer’s pathology, reducing the need for confirmatory testing with a negative result.Data from clinical study supports use in primary care for people with varying signs of cognitive decline. Basel, 23 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today it has received CE Mark for its Elecsys® ...

Roche is also developing the Elecsys pTau217 blood test, an in-vitro diagnostic immunoassay for the quantitative determination of the protein Phospho-Tau (217P) in human plasma for use as an aid in identifying amyloid pathology. Recent data presented on Elecsys pTau217 showed that it was able to accurately detect amyloid pathology and was more stable than a pTau217/Aβ42 ratio in blood and plasma samples at room and refrigerator temperatures. Together with the high throughput and full automation of the assay ...

The Management Board of EfTEN Capital AS approved the updated version of the terms and conditions of EfTEN United Property Fund (hereinafter referred to as the Fund) by its decision of 19.06.2025. The Financial Supervision Authority approved the amendments to the Fund's terms and conditions on 20.07.2025. As a result of the amendment to the Fund's terms and conditions, the wording of the Fund's investment restrictions was clarified in clause 3.11 of the terms and conditions. As a result of the clarification ...

VIENNA, Austria – July 23, 2025 – Today, BAWAG Group released its results for the second quarter 2025, reporting a net profit of € 210 million, earnings per share of € 2.65, and a RoTCE of 27.6%. Pre-provision profits were at € 345 million and the cost-income ratio at 37.5%. This resulted in a net profit of € 411 million, earnings per share of € 5.19, and a RoTCE of 26.7% for the first half of 2025. The CET1 ratio was at 13.5% after deducting the share buyback of € 175 million and the dividend accrual of € ...

Global ingredient supplier Corbion has once again demonstrated its strong commitment to sustainability, earning high marks in climate, water, and supplier engagement in CDP's Disclosure Cycle 2024. Corbion's A‑ rating reflects its science-based approach to climate action, as well as its aggressive emission reduction targets established in line with requirements of the Science Based Targets Initiative. A key contributor was the company's commitment to reduce absolute Scope 1 and 2 greenhouse gas emissions by ...

Basel, 23 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved Itovebi™ (inavolisib), in combination with palbociclib (Ibrance®) and fulvestrant, for the treatment of adult patients with PIK3CA-mutated, oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, following recurrence on or within 12 months of completing adjuvant endocrine treatment. "Itovebi is the first treatment ...

"Itovebi is the first treatment of its kind to improve survival outcomes for those living with PIK3CA-mutated, ER-positive advanced breast cancer," said Levi Garraway, MD, PhD, Roche's Chief Medical Officer and Head of Global Product Development. "Therefore, the Itovebi-based regimen may help address an important unmet need for people with this subtype of breast cancer." The approval is based on results from the phase III INAVO120 trial, published in the New England Journal of Medicine in October 2024, whic ...

PRESS RELEASEJuly 23, 2025 RENAULT GROUP BRANDS STAY THE COURSE IN A CHALLENGING ENVIRONMENT Renault Group recorded an increase in its overall sales in the first half of 2025 (+1.3% vs 2024), reaching 1,169,773 vehicles sold.Internationally1, the Renault brand grew by 16.3% with the commercial success of the first models of the International Game Plan.In Europe2, in a passenger car (PC) market down by 1.0%, the Group grew by 5.4% and reached 708,106 registered vehicles. Sandero and Clio are the two top-sell ...

HIAB CORPORATION, HALF-YEAR FINANCIAL REPORT JANUARY–JUNE 2025, 23 JULY 2025 AT 8:00 AM (EEST) Unless otherwise stated, the financial information in this report concerns Hiab's continuing operations. This half-year report is unaudited. April–June 2025 in brief: Orders received increased January–June 2025 in brief: Operating profit increased Hiab's half-year financial report January–June 2025: Strong performance in the first half Key takeaways from the quarter Outlook for 2025 specified Hiab estimates its co ...

Core Viewpoint - Equinor is set to commence the third tranche of its share buy-back program for 2025, amounting to up to USD 1,265 million, with a specific focus on purchasing shares worth up to USD 417.5 million in the market [1][2]. Group 1: Share Buy-Back Program Details - The total share buy-back program for 2025 is up to USD 5 billion, which includes shares to be redeemed from the Norwegian State, and is structured into tranches [2]. - The third tranche will be executed under a non-discretionary agreement with a third party, allowing independent trading decisions [2]. - The maximum number of shares that can be purchased in the market is 84 million, with 67,622,812 shares remaining available at the start of the third tranche [5]. Group 2: Cancellation and Redemption Process - All shares purchased in the third tranche will be cancelled through a capital reduction at the annual general meeting in May 2026 [4]. - The Norwegian State will vote for the cancellation of shares purchased in the market and redeem a proportionate number of its shares to maintain a 67% ownership stake [6][8]. Group 3: Regulatory Compliance - Share purchases will be conducted on the Oslo Stock Exchange and possibly other trading venues within the EEA, adhering to applicable safe harbour conditions and regulations [7]. - The board of directors will propose the cancellation of shares purchased in the third tranche at the annual general meeting in May 2026 [8].